The AA genotype of XRCC5 rs16855458 was associated with an increased risk of both ER+/PR+ and ER−/PR− breast cancer (AA vs. CC: for ER+/PR+, OR = 1.84, 95% CI = 1.10–3.07, p = 0.019; for ER−/PR−, OR = 2.25, 95% CI = 1.14–4.46, p = 0.019), but not after Bonferroni correction. This evidence concerns the gene XRCC5 and breast cancer.